Supernus Pharmaceuticals (SUPN) Stock Research

Today

Midday Fly By: Amazon passes $3T market cap, Astra in tie-up talks with Bristol

+28

11:57 AM

Video: Bristol Myers jumps, AstraZeneca sinks on report of tie-up talks

9:04 AM

Morning Movers: Supernus and Indivior jump following merger pact

9:01 AM

Supernus reports Q2 EPS ($1.01) with items vs. 40c last year

SUPN

6:46 AM

Supernus raises FY26 adjusted earnings view to $150M-$180 from $140M-$170M

SUPN

6:44 AM

Supernus and Indivior announce merger

6:36 AM

Over a week ago

Supernus price target raised by $4 at Cantor Fitzgerald

SUPN

Jul 9, 8:07 AM

Supernus backs FY26 revenue view $840M-$870M, consensus $862.24M

SUPN

May 5, 5:03 PM

Supernus reports Q1 EPS (4c) vs. (21c) last year

SUPN

May 5, 5:02 PM

Supernus enters into asset purchase agreement with Navitor

SUPN

Apr 7, 5:30 PM

Supernus price target raised by $5 at TD Cowen, here's why

SUPN

Feb 25, 7:42 AM

Closing Bell Movers: First Solar down 12% on earnings miss

+16

Feb 24, 7:53 PM

Supernus sees FY26 revenue $840M-$870M, consensus $861.24M

SUPN

Feb 24, 4:24 PM

Supernus reports Q4 EPS (7c) vs 27c last year

SUPN

Feb 24, 4:24 PM

Jefferies sees potential tailwind forming for psychedelics from marijuana shift

Dec 19, 11:04 AM

Supernus price target raised by $5 at Stifel, here's why

SUPN

Dec 19, 7:50 AM

Supernus management to meet virtually with Cantor Fitzgerald

SUPN

Dec 16, 5:14 PM

Supernus raises FY25 revenue view to $685M-$705M from $670M-$700M

SUPN

Nov 4, 5:32 PM

Supernus reports Q3 EPS (80c) vs. 69c last year

SUPN

Nov 4, 5:30 PM

Skyworks upgraded, UnitedHealth downgraded: Wall Street's top analyst calls

+12

Oct 29, 9:35 AM

Supernus initiated with bullish view at BofA, here's why

SUPN

Oct 29, 6:18 AM

Supernus price target raised by $15 at TD Cowen, here's why

SUPN

Oct 23, 8:32 AM

Piper upgrades Supernus on 'promising' Onapgo trajectory

SUPN

Oct 9, 5:18 AM

Proprietary Formulation Technology: Supernus leverages its specialized drug delivery platforms, particularly for extended-release formulations, which enhance efficacy, reduce side effects, and improve patient adherence for its CNS products.

Differentiated Product Portfolio: The company possesses a diverse range of approved treatments for Central Nervous System (CNS) disorders, including ADHD, epilepsy, depression, and Parkinson's disease, reducing reliance on a single blockbuster drug.

Established Commercial Infrastructure: Supernus has a focused and experienced sales and marketing team with deep relationships within the neurology and psychiatry communities, facilitating effective market penetration for its specialized products.

Generic Competition and Patent Expiry Risk: The company's key revenue-generating products, such as Trokendi XR and Oxtellar XR, face significant threats from generic competition and patent expirations, which can lead to substantial revenue declines.

Pipeline Development and Approval Risk: The success of Supernus heavily depends on the successful clinical development, regulatory approval, and subsequent commercialization of its pipeline products, which are uncertain and costly processes.

Product Commercialization and Market Uptake Risk: New product launches, like Qelbree, require effective marketing, sales, and market acceptance by physicians and patients, which may not materialize as anticipated, impacting sales growth.